Literature DB >> 4152826

Cytochrome P-450 difference spectra: effect of chemical structure on type II spectra in mouse hepatic microsomes.

R B Mailman, A P Kulkarni, R C Baker, E Hodgson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4152826

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  10 in total

1.  Spectral changes resulting from the interaction of some N-alkyl nitrosamines and rat liver microsomes.

Authors:  M I Diaz Gomez; J A Castro
Journal:  Experientia       Date:  1977-05-15

2.  The metabolism and binding of catecholamines by the hepatic microsomal mixed-function oxidase of the rat.

Authors:  D McKillop; G Powis
Journal:  Biochem J       Date:  1976-07-15       Impact factor: 3.857

3.  Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.

Authors:  Lauren N Carnevale; Andres S Arango; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2018-11-06       Impact factor: 3.162

4.  Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response.

Authors:  Natalia Mast; Wenchao Zheng; C David Stout; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2013-01-03       Impact factor: 5.157

5.  Cholesterol hydroperoxides as substrates for cholesterol-metabolizing cytochrome P450 enzymes and alternative sources of 25-hydroxycholesterol and other oxysterols.

Authors:  Johan E van Lier; Natalia Mast; Irina A Pikuleva
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-29       Impact factor: 15.336

6.  Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship.

Authors:  D J Back; J F Tjia
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

7.  A structural snapshot of CYP2B4 in complex with paroxetine provides insights into ligand binding and clusters of conformational states.

Authors:  Manish B Shah; Irina Kufareva; Jaime Pascual; Qinghai Zhang; C David Stout; James R Halpert
Journal:  J Pharmacol Exp Ther       Date:  2013-04-30       Impact factor: 4.030

8.  Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.

Authors:  Natalia Mast; Marlin Linger; Irina A Pikuleva
Journal:  Mol Cell Endocrinol       Date:  2012-10-23       Impact factor: 4.102

9.  In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.

Authors:  Natalia Mast; Peter Verwilst; Clayton J Wilkey; F Peter Guengerich; Irina A Pikuleva
Journal:  J Med Chem       Date:  2019-11-03       Impact factor: 7.446

10.  Cimetidine enhancement of cyclophosphamide antitumour activity.

Authors:  R T Dorr; D S Alberts
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.